Trial Profile
Alemtuzumab for severe steroid-refractory gastrointestinal acute graft-versus-host disease.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Dec 2015
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 14 Dec 2015 New trial record